Prognostic factors for acute myeloid leukaemia in adults - biological significance and clinical use

British Journal of Haematology

Volumn 165, Issue 1, 2014, Pages 17-38

  Liersch, Ruediger ^a   Müller Tidow, Carsten ^b   Berdel, Wolfgang E ^b   Krug, Utz ^b  

^a Internal Medicine   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Acute leukaemia; Myeloid leukaemia; Prognostic factors

Indexed keywords

AZACITIDINE; CD135 ANTIGEN; CYTARABINE; GEMTUZUMAB OZOGAMICIN; MICRORNA; NUCLEOPHOSMIN; RETINOIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE; ASXL1 GENE; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CEBPA GENE; CHROMOSOME ABERRATION; CLINICAL DECISION MAKING; CYTOGENETICS; DNMT3A GENE; DRUG MEGADOSE; EPIGENETICS; FLT3 GENE; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC RISK; GERIATRIC ASSESSMENT; HUMAN; IDH1 GENE; IDH2 GENE; IMMUNOPHENOTYPING; MINIMAL RESIDUAL DISEASE; MYELODYSPLASTIC SYNDROME; NPM1 GENE; ONCOGENE RAS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; RUNX1 GENE; TET2 GENE; TP53 GENE; TUMOR MICROENVIRONMENT; WT1 GENE;

ACUTE LEUKAEMIA; MYELOID LEUKAEMIA; PROGNOSTIC FACTORS;

ADULT; HUMANS; LEUKEMIA, MYELOID, ACUTE; PROGNOSIS; RISK FACTORS;

EID: 84896028589     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12750     Document Type: Review

References (225)

1. Abbas, S., Lugthart, S., Kavelaars, F.G., Schelen, A., Koenders, J.E., Zeilemaker, A., van Putten, W.J., Rijneveld, A.W., Lowenberg, B. & Valk, P.J. (2010) Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood, 116, 2122-2126.
2. Agrawal-Singh, S., Isken, F., Agelopoulos, K., Klein, H.U., Thoennissen, N.H., Koehler, G., Hascher, A., Baumer, N., Berdel, W.E., Thiede, C., Ehninger, G., Becker, A., Schlenke, P., Wang, Y., McClelland, M., Krug, U., Koschmieder, S., Buchner, T., Yu, D.Y., Singh, S.V., Hansen, K., Serve, H., Dugas, M. & Muller-Tidow, C. (2012) Genome-wide analysis of histone H3 acetylation patterns in AML identifies PRDX2 as an epigenetically silenced tumor suppressor gene. Blood, 119, 2346-2357.
3. Allen, C., Hills, R.K., Lamb, K., Evans, C., Tinsley, S., Sellar, R., O'Brien, M., Yin, J.L., Burnett, A.K., Linch, D.C. & Gale, R.E. (2013) The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia. Leukemia, 27, 1891-1901.
4. Appelbaum, F.R., Gundacker, H., Head, D.R., Slovak, M.L., Willman, C.L., Godwin, J.E., Anderson, J.E. & Petersdorf, S.H. (2006) Age and acute myeloid leukemia. Blood, 107, 3481-3485.
5. Arellano, M., Pakkala, S., Langston, A., Tighiouart, M., Pan, L., Chen, Z., Heffner, L.T., Lonial, S., Winton, E. & Khoury, H.J. (2012) Early clearance of peripheral blood blasts predicts response to induction chemotherapy in acute myeloid leukemia. Cancer, 118, 5278-5282.
6. Bacher, U., Kern, W., Schnittger, S., Hiddemann, W., Haferlach, T. & Schoch, C. (2005) Population-based age-specific incidences of cytogenetic subgroups of acute myeloid leukemia. Haematologica, 90, 1502-1510.
7. Bacher, U., Haferlach, C., Kern, W., Haferlach, T. & Schnittger, S. (2008) Prognostic relevance of FLT3-TKD mutations in AML: the combination matters-an analysis of 3082 patients. Blood, 111, 2527-2537.
8. Baldus, C.D., Tanner, S.M., Ruppert, A.S., Whitman, S.P., Archer, K.J., Marcucci, G., Caligiuri, M.A., Carroll, A.J., Vardiman, J.W., Powell, B.L., Allen, S.L., Moore, J.O., Larson, R.A., Kolitz, J.E., de la Chapelle, A. & Bloomfield, C.D. (2003) BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. Blood, 102, 1613-1618.
9. Barjesteh van Waalwijk van Doorn-Khosrovani, S., Erpelinck, C., van Putten, W.L., Valk, P.J., van der Poel-van de Luytgaarde, S., Hack, R., Slater, R., Smit, E.M., Beverloo, H.B., Verhoef, G., Verdonck, L.F., Ossenkoppele, G.J., Sonneveld, P., de Greef, G.E., Lowenberg, B. & Delwel, R. (2003) High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood, 101, 837-845.
10. Becker, H., Marcucci, G., Maharry, K., Radmacher, M.D., Mrozek, K., Margeson, D., Whitman, S.P., Wu, Y.Z., Schwind, S., Paschka, P., Powell, B.L., Carter, T.H., Kolitz, J.E., Wetzler, M., Carroll, A.J., Baer, M.R., Caligiuri, M.A., Larson, R.A. & Bloomfield, C.D. (2010) Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. Journal of Clinical Oncology, 28, 596-604.
11. Behl, D., Porrata, L.F., Markovic, S.N., Letendre, L., Pruthi, R.K., Hook, C.C., Tefferi, A., Elliot, M.A., Kaufmann, S.H., Mesa, R.A. & Litzow, M.R. (2006) Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia, 20, 29-34.
12. Beitinjaneh, A., Jang, S., Roukoz, H. & Majhail, N.S. (2010) Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations in acute promyelocytic leukemia: a systematic review. Leukemia Research, 34, 831-836.
13. Bergmann, L., Miething, C., Maurer, U., Brieger, J., Karakas, T., Weidmann, E. & Hoelzer, D. (1997) High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood, 90, 1217-1225.
14. Bjorklund, E., Gruber, A., Mazur, J., Martensson, A., Hansson, M. & Porwit, A. (2009) CD34 + cell subpopulations detected by 8-color flow cytometry in bone marrow and in peripheral blood stem cell collections: application for MRD detection in leukemia patients. International Journal of Hematology, 90, 292-302.
15. Bloomfield, C.D., Goldman, A., Hassfeld, D. & de la Chapelle, A. (1984) Fourth International Workshop on Chromosomes in Leukemia 1982: clinical significance of chromosomal abnormalities in acute nonlymphoblastic leukemia. Cancer Genetics & Cytogenetics, 11, 332-350.
16. Bloomfield, C.D., Lawrence, D., Byrd, J.C., Carroll, A., Pettenati, M.J., Tantravahi, R., Patil, S.R., Davey, F.R., Berg, D.T., Schiffer, C.A., Arthur, D.C. & Mayer, R.J. (1998) Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Research, 58, 4173-4179.
17. Boissel, N., Leroy, H., Brethon, B., Philippe, N., de Botton, S., Auvrignon, A., Raffoux, E., Leblanc, T., Thomas, X., Hermine, O., Quesnel, B., Baruchel, A., Leverger, G., Dombret, H. & Preudhomme, C. (2006) Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia, 20, 965-970.
18. Boissel, N., Nibourel, O., Renneville, A., Gardin, C., Reman, O., Contentin, N., Bordessoule, D., Pautas, C., de Revel, T., Quesnel, B., Huchette, P., Philippe, N., Geffroy, S., Terre, C., Thomas, X., Castaigne, S., Dombret, H. & Preudhomme, C. (2010) Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group. Journal of Clinical Oncology, 28, 3717-3723.
19. Bornhauser, M., Illmer, T., Schaich, M., Soucek, S., Ehninger, G., Thiede, C. & Group A.S.S. (2007) Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML. Blood, 109, 2264-2265; author reply 2265.
20. Breccia, M., Frustaci, A.M., Cannella, L., Stefanizzi, C., Latagliata, R., Cartoni, C., Diverio, D., Guarini, A., Nanni, M., Rago, A., Cimino, G. & Alimena, G. (2009) Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in elderly acute myeloid leukaemia patients. Hematological Oncology, 27, 148-153.
21. Breems, D.A., Van Putten, W.L., De Greef, G.E., Van Zelderen-Bhola, S.L., Gerssen-Schoorl, K.B., Mellink, C.H., Nieuwint, A., Jotterand, M., Hagemeijer, A., Beverloo, H.B. & Lowenberg, B. (2008) Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. Journal of Clinical Oncology, 26, 4791-4797.
22. Buccisano, F., Maurillo, L., Spagnoli, A., Del Principe, M.I., Fraboni, D., Panetta, P., Ottone, T., Consalvo, M.I., Lavorgna, S., Bulian, P., Ammatuna, E., Angelini, D.F., Diamantini, A., Campagna, S., Ottaviani, L., Sarlo, C., Gattei, V., Del Poeta, G., Arcese, W., Amadori, S., Lo Coco, F. & Venditti, A. (2010) Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia. Blood, 116, 2295-2303.
23. Buchner, T., Hiddemann, W., Wormann, B., Loffler, H., Gassmann, W., Haferlach, T., Fonatsch, C., Haase, D., Schoch, C., Hossfeld, D., Lengfelder, E., Aul, C., Heyll, A., Maschmeyer, G., Ludwig, W.D., Sauerland, M.C. & Heinecke, A. (1999) Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood, 93, 4116-4124.
24. Buchner, T., Berdel, W.E. & Kienast, J. (2008) Cytogenetically normal acute myeloid leukemia. New England Journal of Medicine, 359, 651; author reply 652-653.
25. Buchner, T., Berdel, W.E., Haferlach, C., Schnittger, S., Haferlach, T., Serve, H., Muller-Tidow, C., Braess, J., Spiekermann, K., Kienast, J., Mesters, R., Volpert, S., Staib, P., Gruneisen, A., Kern, W., Reichle, A., Ludwig, W.-D., Maschmeyer, G., Balleisen, L., Eimermacher, H., Aul, C., Giagounidis, A., Rasche, H., Hehlmann, R., Lengfelder, E., Kopcke, W., Krug, U.O., Sauerland, M.C., Heinecke, A., Woermann, B.J. & Hiddemann, W. (2009a) Long-term results in patients with acute myeloid leukemia (AML): the influence of high-dose AraC, G-CSF priming, autologous transplantation, prolonged maintenance, age, history, cytogenetics, and mutation status. Data of the AMLCG 1999 Trial. Blood (ASH Annual Meeting Abstracts), 114, 485.
26. Buchner, T., Berdel, W.E., Haferlach, C., Haferlach, T., Schnittger, S., Muller-Tidow, C., Braess, J., Spiekermann, K., Kienast, J., Staib, P., Gruneisen, A., Kern, W., Reichle, A., Maschmeyer, G., Aul, C., Lengfelder, E., Sauerland, M.C., Heinecke, A., Wormann, B. & Hiddemann, W. (2009b) Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. Journal of Clinical Oncology, 27, 61-69.
27. Bullinger, L., Dohner, K., Bair, E., Frohling, S., Schlenk, R.F., Tibshirani, R., Dohner, H. & Pollack, J.R. (2004) Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. New England Journal of Medicine, 350, 1605-1616.
28. Bullinger, L., Ehrich, M., Dohner, K., Schlenk, R.F., Dohner, H., Nelson, M.R. & van den Boom, D. (2010) Quantitative DNA methylation predicts survival in adult acute myeloid leukemia. Blood, 115, 636-642.
29. Burnett, A.K., Milligan, D., Prentice, A.G., Goldstone, A.H., McMullin, M.F., Hills, R.K. & Wheatley, K. (2007) A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer, 109, 1114-1124.
30. Burnett, A.K., Hills, R.K., Green, C., Jenkinson, S., Koo, K., Patel, Y., Guy, C., Gilkes, A., Milligan, D.W., Goldstone, A.H., Prentice, A.G., Wheatley, K., Linch, D.C. & Gale, R.E. (2010) The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA. Blood, 115, 948-956.
31. Burnett, A.K., Russell, N.H., Hills, R.K., Kell, J., Freeman, S., Kjeldsen, L., Hunter, A.E., Yin, J., Craddock, C.F., Dufva, I.H., Wheatley, K. & Milligan, D. (2012) Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. Journal of Clinical Oncology, 30, 3924-3931.
32. Burnett, A.K., Hills, R.K., Hunter, A.E., Milligan, D., Kell, W.J., Wheatley, K., Yin, J., McMullin, M.F., Dignum, H., Bowen, D., Russell, N.H. & for the UK National Cancer Research Institute AML Working Group. (2013) The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison. Leukemia, 27, 75-81.
33. Cairoli, R., Beghini, A., Grillo, G., Nadali, G., Elice, F., Ripamonti, C.B., Colapietro, P., Nichelatti, M., Pezzetti, L., Lunghi, M., Cuneo, A., Viola, A., Ferrara, F., Lazzarino, M., Rodeghiero, F., Pizzolo, G., Larizza, L. & Morra, E. (2006) Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood, 107, 3463-3468.
34. Cancer Genome Atlas Research, N. (2013) Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. New England Journal of Medicine, 368, 2059-2074.
35. Care, R.S., Valk, P.J., Goodeve, A.C., Abu-Duhier, F.M., Geertsma-Kleinekoort, W.M., Wilson, G.A., Gari, M.A., Peake, I.R., Lowenberg, B. & Reilly, J.T. (2003) Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. British Journal of Haematology, 121, 775-777.
36. Castaigne, S., Pautas, C., Terre, C., Raffoux, E., Bordessoule, D., Bastie, J.N., Legrand, O., Thomas, X., Turlure, P., Reman, O., de Revel, T., Gastaud, L., de Gunzburg, N., Contentin, N., Henry, E., Marolleau, J.P., Aljijakli, A., Rousselot, P., Fenaux, P., Preudhomme, C., Chevret, S., Dombret, H. & Acute Leukemia French, A. (2012) Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet, 379, 1508-1516.
37. Chen, C.C., Yang, C.F., Yang, M.H., Lee, K.D., Kwang, W.K., You, J.Y., Yu, Y.B., Ho, C.H., Tzeng, C.H., Chau, W.K., Hsu, H.C. & Gau, J.P. (2005) Pretreatment prognostic factors and treatment outcome in elderly patients with de novo acute myeloid leukemia. Annals of Oncology, 16, 1366-1373.
38. Chotirat, S., Thongnoppakhun, W., Promsuwicha, O., Boonthimat, C. & Auewarakul, C.U. (2012) Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients. Journal of Hematology & Oncology, 5, 5.
39. Chou, W.C., Hou, H.A., Chen, C.Y., Tang, J.L., Yao, M., Tsay, W., Ko, B.S., Wu, S.J., Huang, S.Y., Hsu, S.C., Chen, Y.C., Huang, Y.N., Chang, Y.C., Lee, F.Y., Liu, M.C., Liu, C.W., Tseng, M.H., Huang, C.F. & Tien, H.F. (2010a) Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood, 115, 2749-2754.
40. Chou, W.C., Huang, H.H., Hou, H.A., Chen, C.Y., Tang, J.L., Yao, M., Tsay, W., Ko, B.S., Wu, S.J., Huang, S.Y., Hsu, S.C., Chen, Y.C., Huang, Y.N., Chang, Y.C., Lee, F.Y., Liu, M.C., Liu, C.W., Tseng, M.H., Huang, C.F. & Tien, H.F. (2010b) Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations. Blood, 116, 4086-4094.
41. Chou, W.C., Chou, S.C., Liu, C.Y., Chen, C.Y., Hou, H.A., Kuo, Y.Y., Lee, M.C., Ko, B.S., Tang, J.L., Yao, M., Tsay, W., Wu, S.J., Huang, S.Y., Hsu, S.C., Chen, Y.C., Chang, Y.C., Kuo, K.T., Lee, F.Y., Liu, M.C., Liu, C.W., Tseng, M.H., Huang, C.F. & Tien, H.F. (2011a) TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood, 118, 3803-3810.
42. Chou, W.C., Lei, W.C., Ko, B.S., Hou, H.A., Chen, C.Y., Tang, J.L., Yao, M., Tsay, W., Wu, S.J., Huang, S.Y., Hsu, S.C., Chen, Y.C., Chang, Y.C., Kuo, K.T., Lee, F.Y., Liu, M.C., Liu, C.W., Tseng, M.H., Huang, C.F. & Tien, H.F. (2011b) The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia. Leukemia, 25, 246-253.
43. Cilloni, D., Renneville, A., Hermitte, F., Hills, R.K., Daly, S., Jovanovic, J.V., Gottardi, E., Fava, M., Schnittger, S., Weiss, T., Izzo, B., Nomdedeu, J., van der Heijden, A., van der Reijden, B.A., Jansen, J.H., van der Velden, V.H., Ommen, H., Preudhomme, C., Saglio, G. & Grimwade, D. (2009) Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. Journal of Clinical Oncology, 27, 5195-5201.
44. Cornelissen, J.J., van Putten, W.L., Verdonck, L.F., Theobald, M., Jacky, E., Daenen, S.M., van Marwijk Kooy, M., Wijermans, P., Schouten, H., Huijgens, P.C., van der Lelie, H., Fey, M., Ferrant, A., Maertens, J., Gratwohl, A. & Lowenberg, B. (2007) Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood, 109, 3658-3666.
45. Creutzig, U., Buchner, T., Sauerland, M.C., Zimmermann, M., Reinhardt, D., Dohner, H. & Schlenk, R.F. (2008) Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A. Cancer, 112, 562-571.
46. Damm, F., Heuser, M., Morgan, M., Yun, H., Grosshennig, A., Gohring, G., Schlegelberger, B., Dohner, K., Ottmann, O., Lubbert, M., Heit, W., Kanz, L., Schlimok, G., Raghavachar, A., Fiedler, W., Kirchner, H., Dohner, H., Heil, G., Ganser, A. & Krauter, J. (2010) Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia. Journal of Clinical Oncology, 28, 578-585.
47. Damm, F., Heuser, M., Morgan, M., Wagner, K., Gorlich, K., Grosshennig, A., Hamwi, I., Thol, F., Surdziel, E., Fiedler, W., Lubbert, M., Kanz, L., Reuter, C., Heil, G., Delwel, R., Lowenberg, B., Valk, P.J., Krauter, J. & Ganser, A. (2011a) Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. Blood, 117, 4561-4568.
48. Damm, F., Oberacker, T., Thol, F., Surdziel, E., Wagner, K., Chaturvedi, A., Morgan, M., Bomm, K., Gohring, G., Lubbert, M., Kanz, L., Fiedler, W., Schlegelberger, B., Heil, G., Schlenk, R.F., Dohner, K., Dohner, H., Krauter, J., Ganser, A. & Heuser, M. (2011b) Prognostic importance of histone methyltransferase MLL5 expression in acute myeloid leukemia. Journal of Clinical Oncology, 29, 682-689.
49. Dankbar, B., Padro, T., Leo, R., Feldmann, B., Kropff, M., Mesters, R.M., Serve, H., Berdel, W.E. & Kienast, J. (2000) Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood, 95, 2630-2636.
50. Daver, N., Liu Dumlao, T., Ravandi, F., Pierce, S., Borthakur, G., Pemmaraju, N., Nazha, A., Faderl, S., Jabbour, E., Garcia-Manero, G., Cortes, J., Kantarjian, H. & Quintás-Cardama, A. (2013) Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy. Clinical Lymphoma Myeloma and Leukemia, 13, 435-440.
51. De Angulo, G., Yuen, C., Palla, S.L., Anderson, P.M. & Zweidler-McKay, P.A. (2008) Absolute lymphocyte count is a novel prognostic indicator in ALL and AML: implications for risk stratification and future studies. Cancer, 112, 407-415.
52. Deneberg, S., Grovdal, M., Karimi, M., Jansson, M., Nahi, H., Corbacioglu, A., Gaidzik, V., Dohner, K., Paul, C., Ekstrom, T.J., Hellstrom-Lindberg, E. & Lehmann, S. (2010) Gene-specific and global methylation patterns predict outcome in patients with acute myeloid leukemia. Leukemia, 24, 932-941.
53. Deneberg, S., Guardiola, P., Lennartsson, A., Qu, Y., Gaidzik, V., Blanchet, O., Karimi, M., Bengtzen, S., Nahi, H., Uggla, B., Tidefelt, U., Hoglund, M., Paul, C., Ekwall, K., Dohner, K. & Lehmann, S. (2011) Prognostic DNA methylation patterns in cytogenetically normal acute myeloid leukemia are predefined by stem cell chromatin marks. Blood, 118, 5573-5582.
54. Deschler, B., Ihorst, G., Platzbecker, U., Germing, U. & Lübbert, M. (2009) Development of a frailty score for older patients with myelodysplastic syndromes and acute myeloid leukemia. Blood, 114, A1775.
55. Deschler, B., Ihorst, G., Platzbecker, U., Germing, U., März, E., de Figuerido, M., Fritzsche, K., Haas, P., Salih, H.R., Giagounidis, A., Selleslag, D., Labar, B., de Witte, T., Wijermans, P. & Lübbert, M. (2013) Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome. Haematologica, 98, 208-216.
56. Dohner, K., Tobis, K., Ulrich, R., Frohling, S., Benner, A., Schlenk, R.F. & Dohner, H. (2002) Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. Journal of Clinical Oncology, 20, 3254-3261.
57. Dohner, K., Schlenk, R.F., Habdank, M., Scholl, C., Rucker, F.G., Corbacioglu, A., Bullinger, L., Frohling, S. & Dohner, H. (2005) Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood, 106, 3740-3746.
58. Dohner, H., Estey, E.H., Amadori, S., Appelbaum, F.R., Buchner, T., Burnett, A.K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R.A., Lo-Coco, F., Naoe, T., Niederwieser, D., Ossenkoppele, G.J., Sanz, M.A., Sierra, J., Tallman, M.S., Lowenberg, B., Bloomfield, C.D. & European, L. (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood, 115, 453-474.
59. van Dongen, J.J., Lhermitte, L., Bottcher, S., Almeida, J., van der Velden, V.H., Flores-Montero, J., Rawstron, A., Asnafi, V., Lecrevisse, Q., Lucio, P., Mejstrikova, E., Szczepanski, T., Kalina, T., de Tute, R., Bruggemann, M., Sedek, L., Cullen, M., Langerak, A.W., Mendonca, A., Macintyre, E., Martin-Ayuso, M., Hrusak, O., Vidriales, M.B., Orfao, A. & EuroFlow, C. (2012) EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia, 26, 1908-1975.
60. Dufour, A., Schneider, F., Metzeler, K.H., Hoster, E., Schneider, S., Zellmeier, E., Benthaus, T., Sauerland, M.C., Berdel, W.E., Buchner, T., Wormann, B., Braess, J., Hiddemann, W., Bohlander, S.K. & Spiekermann, K. (2010) Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. Journal of Clinical Oncology, 28, 570-577.
61. Eisfeld, A.K., Marcucci, G., Maharry, K., Schwind, S., Radmacher, M.D., Nicolet, D., Becker, H., Mrozek, K., Whitman, S.P., Metzeler, K.H., Mendler, J.H., Wu, Y.Z., Liyanarachchi, S., Patel, R., Baer, M.R., Powell, B.L., Carter, T.H., Moore, J.O., Kolitz, J.E., Wetzler, M., Caligiuri, M.A., Larson, R.A., Tanner, S.M., de la Chapelle, A. & Bloomfield, C.D. (2012) miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia. Blood, 120, 249-258.
62. Elliott, M.A., Litzow, M.R., Letendre, L.L., Wolf, R.C., Hanson, C.A., Tefferi, A. & Tallman, M.S. (2007) Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival. Blood, 110, 4172-4174.
63. Etienne, A., Esterni, B., Charbonnier, A., Mozziconacci, M.J., Arnoulet, C., Coso, D., Puig, B., Gastaut, J.A., Maraninchi, D. & Vey, N. (2007) Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia. Cancer, 109, 1376-1383.
64. Falini, B., Mecucci, C., Tiacci, E., Alcalay, M., Rosati, R., Pasqualucci, L., La Starza, R., Diverio, D., Colombo, E., Santucci, A., Bigerna, B., Pacini, R., Pucciarini, A., Liso, A., Vignetti, M., Fazi, P., Meani, N., Pettirossi, V., Saglio, G., Mandelli, F., Lo-Coco, F., Pelicci, P.G. & Martelli, M.F. (2005) Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. New England Journal of Medicine, 352, 254-266.
65. Fenaux, P., Mufti, G.J., Hellstrom-Lindberg, E., Santini, V., Gattermann, N., Germing, U., Sanz, G., List, A.F., Gore, S., Seymour, J.F., Dombret, H., Backstrom, J., Zimmerman, L., McKenzie, D., Beach, C.L. & Silverman, L.R. (2010) Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. Journal of Clinical Oncology, 28, 562-569.
66. Feng, J.H., Guo, X.P., Chen, Y.Y., Wang, Z.J., Cheng, Y.P. & Tang, Y.M. (2012) Prognostic significance of IDH1 mutations in acute myeloid leukemia: a meta-analysis. American Journal of Blood Research, 2, 254-264.
67. Ferrara, F. & Mirto, S. (1996) Serum LDH value as a predictor of clinical outcome in acute myelogenous leukaemia of the elderly. British Journal of Haematology, 92, 627-631.
68. Figueroa, M.E., Lugthart, S., Li, Y., Erpelinck-Verschueren, C., Deng, X., Christos, P.J., Schifano, E., Booth, J., van Putten, W., Skrabanek, L., Campagne, F., Mazumdar, M., Greally, J.M., Valk, P.J., Lowenberg, B., Delwel, R. & Melnick, A. (2010) DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell, 17, 13-27.
69. Frohling, S., Schlenk, R.F., Breitruck, J., Benner, A., Kreitmeier, S., Tobis, K., Dohner, H. & Dohner, K. (2002) Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood, 100, 4372-4380.
70. Gaidzik, V.I., Schlenk, R.F., Moschny, S., Becker, A., Bullinger, L., Corbacioglu, A., Krauter, J., Schlegelberger, B., Ganser, A., Dohner, H. & Dohner, K. (2009) Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. Blood, 113, 4505-4511.
71. Gaidzik, V.I., Paschka, P., Spath, D., Habdank, M., Kohne, C.H., Germing, U., von Lilienfeld-Toal, M., Held, G., Horst, H.A., Haase, D., Bentz, M., Gotze, K., Dohner, H., Schlenk, R.F., Bullinger, L. & Dohner, K. (2012) TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group. Journal of Clinical Oncology, 30, 1350-1357.
72. Gaidzik, V.I., Schlenk, R.F., Paschka, P., Stölzle, A., Späth, D., Kuendgen, A., von Lilienfeld-Toal, M., Brugger, W., Derigs, H.G., Kremers, S., Greil, R., Raghavachar, A., Ringhoffer, M., Salih, H.R., Wattad, M., Kirchen, H.G., Runde, V., Heil, G., Petzer, A.L., Girschikofsky, M., Heuser, M., Kayser, S., Goehring, G., Teleanu, M.V., Schlegelberger, B., Ganser, A., Krauter, J., Bullinger, L., Döhner, H. & Döhner, K. (2013) Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG). Blood, 121, 4769-4777.
73. Gale, R.E., Hills, R., Kottaridis, P.D., Srirangan, S., Wheatley, K., Burnett, A.K. & Linch, D.C. (2005) No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood, 106, 3658-3665.
74. Gale, R.E., Green, C., Allen, C., Mead, A.J., Burnett, A.K., Hills, R.K., Linch, D.C. & Medical Research Council Adult Leukaemia Working, P. (2008) The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood, 111, 2776-2784.
75. Gianfaldoni, G., Mannelli, F., Baccini, M., Antonioli, E., Leoni, F. & Bosi, A. (2006) Clearance of leukaemic blasts from peripheral blood during standard induction treatment predicts the bone marrow response in acute myeloid leukaemia: a pilot study. British Journal of Haematology, 134, 54-57.
76. Gianfaldoni, G., Mannelli, F., Ponziani, V., Longo, G., Bencini, S., Bosi, A. & Vannucchi, A.M. (2010) Early reduction of WT1 transcripts during induction chemotherapy predicts for longer disease free and overall survival in acute myeloid leukemia. Haematologica, 95, 833-836.
77. Giles, F.J., Borthakur, G., Ravandi, F., Faderl, S., Verstovsek, S., Thomas, D., Wierda, W., Ferrajoli, A., Kornblau, S., Pierce, S., Albitar, M., Cortes, J. & Kantarjian, H. (2007) The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. British Journal of Haematology, 136, 624-627.
78. Gombart, A.F., Hofmann, W.K., Kawano, S., Takeuchi, S., Krug, U., Kwok, S.H., Larsen, R.J., Asou, H., Miller, C.W., Hoelzer, D. & Koeffler, H.P. (2002) Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias. Blood, 99, 1332-1340.
79. Gonen, M., Sun, Z., Figueroa, M.E., Patel, J.P., Abdel-Wahab, O., Racevskis, J., Ketterling, R.P., Fernandez, H., Rowe, J.M., Tallman, M.S., Melnick, A., Levine, R.L. & Paietta, E. (2012) CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900. Blood, 120, 2297-2306.
80. Gordon, J.E., Wong, J.J. & Rasko, J.E. (2013) MicroRNAs in myeloid malignancies. British Journal of Haematology, 162, 162-176.
81. Green, C.L., Koo, K.K., Hills, R.K., Burnett, A.K., Linch, D.C. & Gale, R.E. (2010a) Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. Journal of Clinical Oncology, 28, 2739-2747.
82. Green, C.L., Evans, C.M., Hills, R.K., Burnett, A.K., Linch, D.C. & Gale, R.E. (2010b) The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status. Blood, 116, 2779-2782.
83. Green, C.L., Evans, C.M., Zhao, L., Hills, R.K., Burnett, A.K., Linch, D.C. & Gale, R.E. (2011) The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood, 118, 409-412.
84. Grimwade, D., Hills, R.K., Moorman, A.V., Walker, H., Chatters, S., Goldstone, A.H., Wheatley, K., Harrison, C.J. & Burnett, A.K. (2010) Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities amongst 5, 876 younger adult patients treated in the UK Medical Research Council trials. Blood, 116, 354-365.
85. Grossmann, V., Schnittger, S., Kohlmann, A., Eder, C., Roller, A., Dicker, F., Schmid, C., Wendtner, C.M., Staib, P., Serve, H., Kreuzer, K.A., Kern, W., Haferlach, T. & Haferlach, C. (2012) A novel hierarchical prognostic model of AML solely based on molecular mutations. Blood, 120, 2963-2972.
86. Guan, Y. & Hogge, D.E. (2000) Proliferative status of primitive hematopoietic progenitors from patients with acute myelogenous leukemia (AML). Leukemia, 14, 2135-2141.
87. Guzman, M.L., Neering, S.J., Upchurch, D., Grimes, B., Howard, D.S., Rizzieri, D.A., Luger, S.M. & Jordan, C.T. (2001) Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood, 98, 2301-2307.
88. Haferlach, C., Dicker, F., Herholz, H., Schnittger, S., Kern, W. & Haferlach, T. (2008) Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype. Leukemia, 22, 1539-1541.
89. Heuser, M., Beutel, G., Krauter, J., Dohner, K., von Neuhoff, N., Schlegelberger, B. & Ganser, A. (2006) High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood, 108, 3898-3905.
90. Ho, P.A., Alonzo, T.A., Kopecky, K.J., Miller, K.L., Kuhn, J., Zeng, R., Gerbing, R.B., Raimondi, S.C., Hirsch, B.A., Oehler, V., Hurwitz, C.A., Franklin, J.L., Gamis, A.S., Petersdorf, S.H., Anderson, J.E., Reaman, G.H., Baker, L.H., Willman, C.L., Bernstein, I.D., Radich, J.P., Appelbaum, F.R., Stirewalt, D.L. & Meshinchi, S. (2010) Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study. Leukemia, 24, 909-913.
91. Hope, K.J., Jin, L. & Dick, J.E. (2004) Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nature Immunology, 5, 738-743.
92. Hosen, N., Park, C.Y., Tatsumi, N., Oji, Y., Sugiyama, H., Gramatzki, M., Krensky, A.M. & Weissman, I.L. (2007) CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America, 104, 11008-11013.
93. Hou, H.A., Kuo, Y.Y., Liu, C.Y., Chou, W.C., Lee, M.C., Chen, C.Y., Lin, L.I., Tseng, M.H., Huang, C.F., Chiang, Y.C., Lee, F.Y., Liu, M.C., Liu, C.W., Tang, J.L., Yao, M., Huang, S.Y., Ko, B.S., Hsu, S.C., Wu, S.J., Tsay, W., Chen, Y.C. & Tien, H.F. (2012) DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. Blood, 119, 559-568.
94. Iriyama, N., Hatta, Y., Takeuchi, J., Ogawa, Y., Ohtake, S., Sakura, T., Mitani, K., Ishida, F., Takahashi, M., Maeda, T., Izumi, T., Sakamaki, H., Miyawaki, S., Honda, S., Miyazaki, Y., Taki, T., Taniwaki, M. & Naoe, T. (2013) CD56 expression is an independent prognostic factor for relapse in acute myeloid leukemia with t(8;21). Leukemia Research, 37, 1021-1026.
95. Itzykson, R., Kosmider, O., Cluzeau, T., Mansat-De Mas, V., Dreyfus, F., Beyne-Rauzy, O., Quesnel, B., Vey, N., Gelsi-Boyer, V., Raynaud, S., Preudhomme, C., Ades, L., Fenaux, P., Fontenay, M. & Groupe Francophone des M. (2011) Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia, 25, 1147-1152.
96. Jaiswal, S., Jamieson, C.H., Pang, W.W., Park, C.Y., Chao, M.P., Majeti, R., Traver, D., van Rooijen, N. & Weissman, I.L. (2009) CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell, 138, 271-285.
97. de Jonge, H.J., Valk, P.J., de Bont, E.S., Schuringa, J.J., Ossenkoppele, G., Vellenga, E. & Huls, G. (2011) Prognostic impact of white blood cell count in intermediate risk acute myeloid leukemia: relevance of mutated NPM1 and FLT3-ITD. Haematologica, 96, 1310-1317.
98. Jourdan, E., Boissel, N., Chevret, S., Delabesse, E., Renneville, A., Cornillet, P., Blanchet, O., Cayuela, J.M., Recher, C., Raffoux, E., Delaunay, J., Pigneux, A., Bulabois, C.E., Berthon, C., Pautas, C., Vey, N., Lioure, B., Thomas, X., Luquet, I., Terre, C., Guardiola, P., Bene, M.C., Preudhomme, C., Ifrah, N., Dombret, H. & French, A.M.L.I. (2013) Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood, 121, 2213-2223.
99. Juliusson, G., Antunovic, P., Derolf, A., Lehmann, S., Mollgard, L., Stockelberg, D., Tidefelt, U., Wahlin, A. & Hoglund, M. (2009) Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood, 113, 4179-4187.
100. Kantarjian, H., O'Brien, S., Cortes, J., Giles, F., Faderl, S., Jabbour, E., Garcia-Manero, G., Wierda, W., Pierce, S., Shan, J. & Estey, E. (2006) Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer, 106, 1090-1098.
101. Kantarjian, H.M., Thomas, X.G., Dmoszynska, A., Wierzbowska, A., Mazur, G., Mayer, J., Gau, J.P., Chou, W.C., Buckstein, R., Cermak, J., Kuo, C.Y., Oriol, A., Ravandi, F., Faderl, S., Delaunay, J., Lysak, D., Minden, M. & Arthur, C. (2012) Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. Journal of Clinical Oncology, 30, 2670-2677.
102. Kayser, S., Schlenk, R.F., Londono, M.C., Breitenbuecher, F., Wittke, K., Du, J., Groner, S., Spath, D., Krauter, J., Ganser, A., Dohner, H., Fischer, T., Dohner, K. & German-Austrian, A.M.L.S.G. (2009) Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. Blood, 114, 2386-2392.
103. Kayser, S., Dohner, K., Krauter, J., Kohne, C.H., Horst, H.A., Held, G., von Lilienfeld-Toal, M., Wilhelm, S., Kundgen, A., Gotze, K., Rummel, M., Nachbaur, D., Schlegelberger, B., Gohring, G., Spath, D., Morlok, C., Zucknick, M., Ganser, A., Dohner, H., Schlenk, R.F. & German-Austrian, A. (2011) The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood, 117, 2137-2145.
104. Kayser, S., Zucknick, M., Dohner, K., Krauter, J., Kohne, C.H., Horst, H.A., Held, G., von Lilienfeld-Toal, M., Wilhelm, S., Rummel, M., Germing, U., Gotze, K., Nachbaur, D., Schlegelberger, B., Gohring, G., Spath, D., Morlok, C., Teleanu, V., Ganser, A., Dohner, H., Schlenk, R.F. & German-Austrian AML Study Group. (2012) Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies. Blood, 119, 551-558.
105. Keating, M.J., Smith, T.L., Gehan, E.A., McCredie, K.B., Bodey, G.P., Spitzer, G., Hersh, E., Gutterman, J. & Freireich, E.J. (1980) Factors related to length of complete remission in adult acute leukemia. Cancer, 45, 2017-2029.
106. Kern, W., Haferlach, T., Schoch, C., Loffler, H., Gassmann, W., Heinecke, A., Sauerland, M.C., Berdel, W., Buchner, T. & Hiddemann, W. (2003) Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood, 101, 64-70.
107. Konoplev, S., Rassidakis, G.Z., Estey, E., Kantarjian, H., Liakou, C.I., Huang, X., Xiao, L., Andreeff, M., Konopleva, M. & Medeiros, L.J. (2007) Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype. Cancer, 109, 1152-1156.
108. Koreth, J., Schlenk, R., Kopecky, K.J., Honda, S., Sierra, J., Djulbegovic, B.J., Wadleigh, M., DeAngelo, D.J., Stone, R.M., Sakamaki, H., Appelbaum, F.R., Dohner, H., Antin, J.H., Soiffer, R.J. & Cutler, C. (2009) Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA, 301, 2349-2361.
109. Kottaridis, P.D., Gale, R.E., Frew, M.E., Harrison, G., Langabeer, S.E., Belton, A.A., Walker, H., Wheatley, K., Bowen, D.T., Burnett, A.K., Goldstone, A.H. & Linch, D.C. (2001) The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood, 98, 1752-1759.
110. Kottaridis, P.D., Gale, R.E., Langabeer, S.E., Frew, M.E., Bowen, D.T. & Linch, D.C. (2002) Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood, 100, 2393-2398.
111. Krauter, J., Gorlich, K., Ottmann, O., Lubbert, M., Dohner, H., Heit, W., Kanz, L., Ganser, A. & Heil, G. (2003) Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias. Journal of Clinical Oncology, 21, 4413-4422.
112. Krauter, J., Wagner, K., Schafer, I., Marschalek, R., Meyer, C., Heil, G., Schaich, M., Ehninger, G., Niederwieser, D., Krahl, R., Buchner, T., Sauerland, C., Schlegelberger, B., Dohner, K., Dohner, H., Schlenk, R.F. & Ganser, A. (2009) Prognostic factors in adult patients up to 60 years old with acute myeloid leukemia and translocations of chromosome band 11q23: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup. Journal of Clinical Oncology, 27, 3000-3006.
113. Kronke, J., Schlenk, R.F., Jensen, K.O., Tschurtz, F., Corbacioglu, A., Gaidzik, V.I., Paschka, P., Onken, S., Eiwen, K., Habdank, M., Spath, D., Lubbert, M., Wattad, M., Kindler, T., Salih, H.R., Held, G., Nachbaur, D., von Lilienfeld-Toal, M., Germing, U., Haase, D., Mergenthaler, H.G., Krauter, J., Ganser, A., Gohring, G., Schlegelberger, B., Dohner, H. & Dohner, K. (2011) Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. Journal of Clinical Oncology, 29, 2709-2716.
114. Krug, U.O., Berdel, W., Amler, S., Sauerland, M.C., Wormann, B., Hiddemann, W. & Buchner, T. (2009) Continuous decrease of overall survival in patients > 30 years of age with acute myelogenous leukemia. Blood (ASH Annual Meeting Abstracts), 114, Abstract 998.
115. Krug, U., Rollig, C., Koschmieder, A., Heinecke, A., Sauerland, M.C., Schaich, M., Thiede, C., Kramer, M., Braess, J., Spiekermann, K., Haferlach, T., Haferlach, C., Koschmieder, S., Rohde, C., Serve, H., Wormann, B., Hiddemann, W., Ehninger, G., Berdel, W.E., Buchner, T. & Muller-Tidow, C. (2010) Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet, 376, 2000-2008.
116. Kusec, R., Jaksic, O., Ostojic, S., Kardum-Skelin, I., Vrhovac, R. & Jaksic, B. (2006) More on prognostic significance of FLT3/ITD size in acute myeloid leukemia (AML). Blood, 108, 405-406; author reply 406.
117. Lacombe, F., Arnoulet, C., Maynadie, M., Lippert, E., Luquet, I., Pigneux, A., Vey, N., Casasnovas, O., Witz, F. & Bene, M.C. (2009) Early clearance of peripheral blasts measured by flow cytometry during the first week of AML induction therapy as a new independent prognostic factor: a GOELAMS study. Leukemia, 23, 350-357.
118. Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., Minden, M., Paterson, B., Caligiuri, M.A. & Dick, J.E. (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature, 367, 645-648.
119. Larson, R.A. (2007) Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia? Best Practice & Research. Clinical Haematology, 20, 29-37.
120. Ley, T.J., Ding, L., Walter, M.J., McLellan, M.D., Lamprecht, T., Larson, D.E., Kandoth, C., Payton, J.E., Baty, J., Welch, J., Harris, C.C., Lichti, C.F., Townsend, R.R., Fulton, R.S., Dooling, D.J., Koboldt, D.C., Schmidt, H., Zhang, Q., Osborne, J.R., Lin, L., O'Laughlin, M., McMichael, J.F., Delehaunty, K.D., McGrath, S.D., Fulton, L.A., Magrini, V.J., Vickery, T.L., Hundal, J., Cook, L.L., Conyers, J.J., Swift, G.W., Reed, J.P., Alldredge, P.A., Wylie, T., Walker, J., Kalicki, J., Watson, M.A., Heath, S., Shannon, W.D., Varghese, N., Nagarajan, R., Westervelt, P., Tomasson, M.H., Link, D.C., Graubert, T.A., DiPersio, J.F., Mardis, E.R. & Wilson, R.K. (2010) DNMT3A mutations in acute myeloid leukemia. New England Journal of Medicine, 363, 2424-2433.
121. Li, Q., Kopecky, K.J., Mohan, A., Willman, C.L., Appelbaum, F.R., Weick, J.K. & Issa, J.P. (1999) Estrogen receptor methylation is associated with improved survival in adult acute myeloid leukemia. Clinical Cancer Research, 5, 1077-1084.
122. Li, Z., Huang, H., Li, Y., Jiang, X., Chen, P., Arnovitz, S., Radmacher, M.D., Maharry, K., Elkahloun, A., Yang, X., He, C., He, M., Zhang, Z., Dohner, K., Neilly, M.B., Price, C., Lussier, Y.A., Zhang, Y., Larson, R.A., Le Beau, M.M., Caligiuri, M.A., Bullinger, L., Valk, P.J., Delwel, R., Lowenberg, B., Liu, P.P., Marcucci, G., Bloomfield, C.D., Rowley, J.D. & Chen, J. (2012) Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. Blood, 119, 2314-2324.
123. Li, Z., Herold, T., He, C., Valk, P.J., Chen, P., Jurinovic, V., Mansmann, U., Radmacher, M.D., Maharry, K.S., Sun, M., Yang, X., Huang, H., Jiang, X., Sauerland, M.C., Buchner, T., Hiddemann, W., Elkahloun, A., Neilly, M.B., Zhang, Y., Larson, R.A., Le Beau, M.M., Caligiuri, M.A., Dohner, K., Bullinger, L., Liu, P.P., Delwel, R., Marcucci, G., Lowenberg, B., Bloomfield, C.D., Rowley, J.D., Bohlander, S.K. & Chen, J. (2013) Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study. Journal of Clinical Oncology, 31, 1172-1181.
124. Liersch, R., Gerss, J., Schliemann, C., Bayer, M., Schwoppe, C., Biermann, C., Appelmann, I., Kessler, T., Lowenberg, B., Buchner, T., Hiddemann, W., Muller-Tidow, C., Berdel, W.E. & Mesters, R. (2012) Osteopontin is a prognostic factor for survival of acute myeloid leukemia patients. Blood, 119, 5215-5220.
125. Lin, T.C., Hou, H.A., Chou, W.C., Ou, D.L., Yu, S.L., Tien, H.F. & Lin, L.I. (2011) CEBPA methylation as a prognostic biomarker in patients with de novo acute myeloid leukemia. Leukemia, 25, 32-40.
126. Loken, M.R., Alonzo, T.A., Pardo, L., Gerbing, R.B., Raimondi, S.C., Hirsch, B.A., Ho, P.A., Franklin, J., Cooper, T.M., Gamis, A.S. & Meshinchi, S. (2012) Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. Blood, 120, 1581-1588.
127. Majeti, R., Chao, M.P., Alizadeh, A.A., Pang, W.W., Jaiswal, S., Gibbs, K.D. Jr, van Rooijen, N. & Weissman, I.L. (2009) CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell, 138, 286-299.
128. Marcucci, G., Baldus, C.D., Ruppert, A.S., Radmacher, M.D., Mrozek, K., Whitman, S.P., Kolitz, J.E., Edwards, C.G., Vardiman, J.W., Powell, B.L., Baer, M.R., Moore, J.O., Perrotti, D., Caligiuri, M.A., Carroll, A.J., Larson, R.A., de la Chapelle, A. & Bloomfield, C.D. (2005) Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. Journal of Clinical Oncology, 23, 9234-9242.
129. Marcucci, G., Maharry, K., Wu, Y.Z., Radmacher, M.D., Mrozek, K., Margeson, D., Holland, K.B., Whitman, S.P., Becker, H., Schwind, S., Metzeler, K.H., Powell, B.L., Carter, T.H., Kolitz, J.E., Wetzler, M., Carroll, A.J., Baer, M.R., Caligiuri, M.A., Larson, R.A. & Bloomfield, C.D. (2010) IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Journal of Clinical Oncology, 28, 2348-2355.
130. Marcucci, G., Metzeler, K.H., Schwind, S., Becker, H., Maharry, K., Mrozek, K., Radmacher, M.D., Kohlschmidt, J., Nicolet, D., Whitman, S.P., Wu, Y.Z., Powell, B.L., Carter, T.H., Kolitz, J.E., Wetzler, M., Carroll, A.J., Baer, M.R., Moore, J.O., Caligiuri, M.A., Larson, R.A. & Bloomfield, C.D. (2012) Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. Journal of Clinical Oncology, 30, 742-750.
131. Marcucci, G., Maharry, K.S., Metzeler, K.H., Volinia, S., Wu, Y.Z., Mrózek, K., Nicolet, D., Kohlschmidt, J., Whitman, S.P., Mendler, J.H., Schwind, S., Becker, H., Eisfeld, A.K., Carroll, A.J., Powell, B.L., Kolitz, J.E., Garzon, R., Caligiuri, M.A., Stone, R.M. & Bloomfield, C.D. (2013) Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. Journal of Clinical Oncology, 31, 2086-2093.
132. Markova, J., Michkova, P., Burckova, K., Brezinova, J., Michalova, K., Dohnalova, A., Maaloufova, J.S., Soukup, P., Vitek, A., Cetkovsky, P. & Schwarz, J. (2012) Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia. European Journal of Haematology, 88, 128-135.
133. Mayer, R.J., Davis, R.B., Schiffer, C.A., Berg, D.T., Powell, B.L., Schulman, P., Omura, G.A., Moore, J.O., McIntyre, O.R. & Frei, E. 3rd (1994) Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. New England Journal of Medicine, 331, 896-903.
134. Mead, A.J., Linch, D.C., Hills, R.K., Wheatley, K., Burnett, A.K. & Gale, R.E. (2007) FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood, 110, 1262-1270.
135. Meshinchi, S., Arceci, R.J., Sanders, J.E., Smith, F.O., Woods, W.B., Radich, J.P. & Alonzo, T.A. (2006) Role of allogeneic stem cell transplantation in FLT3/ITD-positive AML. Blood, 108, 400; author reply 400-401.
136. Metzeler, K.H., Becker, H., Maharry, K., Radmacher, M.D., Kohlschmidt, J., Mrozek, K., Nicolet, D., Whitman, S.P., Wu, Y.Z., Schwind, S., Powell, B.L., Carter, T.H., Wetzler, M., Moore, J.O., Kolitz, J.E., Baer, M.R., Carroll, A.J., Larson, R.A., Caligiuri, M.A., Marcucci, G. & Bloomfield, C.D. (2011) ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood, 118, 6920-6929.
137. Metzeler, K.H., Walker, A., Geyer, S., Garzon, R., Klisovic, R.B., Bloomfield, C.D., Blum, W. & Marcucci, G. (2012a) DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia. Leukemia, 26, 1106-1107.
138. Metzeler, K.H., Maharry, K., Radmacher, M.D., Mrozek, K., Margeson, D., Becker, H., Curfman, J., Holland, K.B., Schwind, S., Whitman, S.P., Wu, Y.Z., Blum, W., Powell, B.L., Carter, T.H., Wetzler, M., Moore, J.O., Kolitz, J.E., Baer, M.R., Carroll, A.J., Larson, R.A., Caligiuri, M.A., Marcucci, G. & Bloomfield, C.D. (2012b) TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. Journal of Clinical Oncology, 29, 1373-1381.
139. Miglino, M., Colombo, N., Pica, G., Grasso, R., Clavio, M., Bergamaschi, M., Ballerini, F., Ghiso, A., Ghiggi, C., Mitscheunig, L., Beltrami, G., Cagnetta, A., Vignolo, L., Lucchetti, M.V., Aquino, S., Pierri, I., Sessarego, M., Carella, A.M. & Gobbi, M. (2011) WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia. Leukemia & Lymphoma, 52, 1961-1969.
140. Miwa, H., Beran, M. & Saunders, G.F. (1992) Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia, 6, 405-409.
141. Muller-Tidow, C., Klein, H.U., Hascher, A., Isken, F., Tickenbrock, L., Thoennissen, N., Agrawal-Singh, S., Tschanter, P., Disselhoff, C., Wang, Y., Becker, A., Thiede, C., Ehninger, G., zur Stadt, U., Koschmieder, S., Seidl, M., Muller, F.U., Schmitz, W., Schlenke, P., McClelland, M., Berdel, W.E., Dugas, M., Serve, H. & Study Alliance L. (2010) Profiling of histone H3 lysine 9 trimethylation levels predicts transcription factor activity and survival in acute myeloid leukemia. Blood, 116, 3564-3571.
142. Naoe, T. & Kiyoi, H. (2013) Gene mutations of acute myeloid leukemia in the genome era. International Journal of Hematology, 97, 165-174.
143. Nazha, A., Bueso-Ramos, C.E., Faderl, S., Estey, E.H., O'Brien, S.M., Farnandez, M., Nguyen, M., Koller, C., Freireich, E., Beran, M., Pierce, S., Cortes, J.E., Kantarjian, H.M. & Ravandi, F. (2012) Addition of All-Trans Retinoic Acid (ATRA) to the Combination of Fludarabine, Cytarabine, Idarubicin, with or without GCSF in Older, Higher Risk Patients with AML and High-Risk MDS Does Not Improve the Outcome in those with NPM1 Mutation. Blood (ASH Annual Meeting Abstracts), 120, Abstract 2616.
144. Neubauer, A., Maharry, K., Mrozek, K., Thiede, C., Marcucci, G., Paschka, P., Mayer, R.J., Larson, R.A., Liu, E.T. & Bloomfield, C.D. (2008) Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study. Journal of Clinical Oncology, 26, 4603-4609.
145. Nilsson, S.K., Johnston, H.M., Whitty, G.A., Williams, B., Webb, R.J., Denhardt, D.T., Bertoncello, I., Bendall, L.J., Simmons, P.J. & Haylock, D.N. (2005) Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells. Blood, 106, 1232-1239.
146. Nomdedeu, J., Hoyos, M., Carricondo, M., Esteve, J., Bussaglia, E., Estivill, C., Ribera, J.M., Duarte, R., Salamero, O., Gallardo, D., Pedro, C., Aventin, A., Brunet, S. & Sierra, J. (2012) Adverse impact of IDH1 and IDH2 mutations in primary AML: experience of the Spanish CETLAM group. Leukemia Research, 36, 990-997.
147. Ohgami, R.S., Ma, L., Ren, L., Weinberg, O.K., Seetharam, M., Gotlib, J.R. & Arber, D.A. (2012) DNA methylation analysis of ALOX12 and GSTM1 in acute myeloid leukaemia identifies prognostically significant groups. British Journal of Haematology, 159, 182-190.
148. Pabst, T., Mueller, B.U., Zhang, P., Radomska, H.S., Narravula, S., Schnittger, S., Behre, G., Hiddemann, W. & Tenen, D.G. (2001) Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nature Genetics, 27, 263-270.
149. Papadaki, C., Dufour, A., Seibl, M., Schneider, S., Bohlander, S.K., Zellmeier, E., Mellert, G., Hiddemann, W. & Spiekermann, K. (2009) Monitoring minimal residual disease in acute myeloid leukaemia with NPM1 mutations by quantitative PCR: clonal evolution is a limiting factor. British Journal of Haematology, 144, 517-523.
150. Paschka, P., Marcucci, G., Ruppert, A.S., Mrozek, K., Chen, H., Kittles, R.A., Vukosavljevic, T., Perrotti, D., Vardiman, J.W., Carroll, A.J., Kolitz, J.E., Larson, R.A. & Bloomfield, C.D. (2006) Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. Journal of Clinical Oncology, 24, 3904-3911.
151. Paschka, P., Marcucci, G., Ruppert, A.S., Whitman, S.P., Mrozek, K., Maharry, K., Langer, C., Baldus, C.D., Zhao, W., Powell, B.L., Baer, M.R., Carroll, A.J., Caligiuri, M.A., Kolitz, J.E., Larson, R.A. & Bloomfield, C.D. (2008) Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. Journal of Clinical Oncology, 26, 4595-4602.
152. Paschka, P., Schlenk, R.F., Gaidzik, V.I., Habdank, M., Kronke, J., Bullinger, L., Spath, D., Kayser, S., Zucknick, M., Gotze, K., Horst, H.A., Germing, U., Dohner, H. & Dohner, K. (2010) IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. Journal of Clinical Oncology, 28, 3636-3643.
153. Paschka, P., Du, J., Schlenk, R.F., Gaidzik, V.I., Bullinger, L., Corbacioglu, A., Spath, D., Kayser, S., Schlegelberger, B., Krauter, J., Ganser, A., Kohne, C.H., Held, G., von Lilienfeld-Toal, M., Kirchen, H., Rummel, M., Gotze, K., Horst, H.A., Ringhoffer, M., Lubbert, M., Wattad, M., Salih, H.R., Kundgen, A., Dohner, H. & Dohner, K. (2013) Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG). Blood, 121, 170-177.
154. Patel, J.P., Gonen, M., Figueroa, M.E., Fernandez, H., Sun, Z., Racevskis, J., Van Vlierberghe, P., Dolgalev, I., Thomas, S., Aminova, O., Huberman, K., Cheng, J., Viale, A., Socci, N.D., Heguy, A., Cherry, A., Vance, G., Higgins, R.R., Ketterling, R.P., Gallagher, R.E., Litzow, M., van den Brink, M.R., Lazarus, H.M., Rowe, J.M., Luger, S., Ferrando, A., Paietta, E., Tallman, M.S., Melnick, A., Abdel-Wahab, O. & Levine, R.L. (2012) Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. New England Journal of Medicine, 366, 1079-1089.
155. Pfirrmann, M., Ehninger, G., Thiede, C., Bornhauser, M., Kramer, M., Rollig, C., Hasford, J., Schaich, M. & Leukemia Study Alliance. (2012) Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial. Lancet Oncology, 13, 207-214.
156. Ponziani, V., Gianfaldoni, G., Mannelli, F., Leoni, F., Ciolli, S., Guglielmelli, P., Antonioli, E., Longo, G., Bosi, A. & Vannucchi, A.M. (2006) The size of duplication does not add to the prognostic significance of FLT3 internal tandem duplication in acute myeloid leukemia patients. Leukemia, 20, 2074-2076.
157. Pratcorona, M., Brunet, S., Nomdedeu, J., Ribera, J.M., Tormo, M., Duarte, R., Escoda, L., Guardia, R., Queipo de Llano, M.P., Salamero, O., Bargay, J., Pedro, C., Marti, J.M., Torrebadell, M., Diaz-Beya, M., Camos, M., Colomer, D., Hoyos, M., Sierra, J., Esteve, J. & Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas, M. (2013) Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. Blood, 121, 2734-2738.
158. Preudhomme, C., Sagot, C., Boissel, N., Cayuela, J.M., Tigaud, I., de Botton, S., Thomas, X., Raffoux, E., Lamandin, C., Castaigne, S., Fenaux, P., Dombret, H. & Group A. (2002) Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood, 100, 2717-2723.
159. Raspadori, D., Damiani, D., Lenoci, M., Rondelli, D., Testoni, N., Nardi, G., Sestigiani, C., Mariotti, C., Birtolo, S., Tozzi, M. & Lauria, F. (2001) CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis. Leukemia, 15, 1161-1164.
160. Ravandi, F., Patel, K., Luthra, R., Faderl, S., Konopleva, M., Kadia, T., Brandt, M., Pierce, S., Kornblau, S., Andreeff, M., Wang, X., Garcia-Manero, G., Cortes, J. & Kantarjian, H. (2012) Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin. Cancer, 118, 2665-2673.
161. Renneville, A., Boissel, N., Nibourel, O., Berthon, C., Helevaut, N., Gardin, C., Cayuela, J.M., Hayette, S., Reman, O., Contentin, N., Bordessoule, D., Pautas, C., Botton, S., Revel, T., Terre, C., Fenaux, P., Thomas, X., Castaigne, S., Dombret, H. & Preudhomme, C. (2012) Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association. Leukemia, 26, 1247-1254.
162. Ribeiro, A.F., Pratcorona, M., Erpelinck-Verschueren, C., Rockova, V., Sanders, M., Abbas, S., Figueroa, M.E., Zeilemaker, A., Melnick, A., Lowenberg, B., Valk, P.J. & Delwel, R. (2012) Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. Blood, 119, 5824-5831.
163. Rockova, V., Abbas, S., Wouters, B.J., Erpelinck, C.A., Beverloo, H.B., Delwel, R., van Putten, W.L., Lowenberg, B. & Valk, P.J. (2011) Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers. Blood, 118, 1069-1076.
164. Rollig, C., Thiede, C., Gramatzki, M., Aulitzky, W., Bodenstein, H., Bornhauser, M., Platzbecker, U., Stuhlmann, R., Schuler, U., Soucek, S., Kramer, M., Mohr, B., Oelschlaegel, U., Stolzel, F., von Bonin, M., Wermke, M., Wandt, H., Ehninger, G. & Schaich, M. (2010) A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial. Blood, 116, 971-978.
165. Rombouts, E.J., Pavic, B., Lowenberg, B. & Ploemacher, R.E. (2004) Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. Blood, 104, 550-557.
166. Rubnitz, J.E., Inaba, H., Dahl, G., Ribeiro, R.C., Bowman, W.P., Taub, J., Pounds, S., Razzouk, B.I., Lacayo, N.J., Cao, X., Meshinchi, S., Degar, B., Airewele, G., Raimondi, S.C., Onciu, M., Coustan-Smith, E., Downing, J.R., Leung, W., Pui, C.H. & Campana, D. (2010) Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncology, 11, 543-552.
167. Rucker, F.G., Schlenk, R.F., Bullinger, L., Kayser, S., Teleanu, V., Kett, H., Habdank, M., Kugler, C.M., Holzmann, K., Gaidzik, V.I., Paschka, P., Held, G., von Lilienfeld-Toal, M., Lubbert, M., Frohling, S., Zenz, T., Krauter, J., Schlegelberger, B., Ganser, A., Lichter, P., Dohner, K. & Dohner, H. (2012) TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood, 119, 2114-2121.
168. Saito, Y., Kitamura, H., Hijikata, A., Tomizawa-Murasawa, M., Tanaka, S., Takagi, S., Uchida, N., Suzuki, N., Sone, A., Najima, Y., Ozawa, H., Wake, A., Taniguchi, S., Shultz, L.D., Ohara, O. & Ishikawa, F. (2010) Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Science Translational Medicine, 2, 17ra19.
169. Schlenk, R.F., Dohner, K., Krauter, J., Frohling, S., Corbacioglu, A., Bullinger, L., Habdank, M., Spath, D., Morgan, M., Benner, A., Schlegelberger, B., Heil, G., Ganser, A. & Dohner, H. (2008) Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. New England Journal of Medicine, 358, 1909-1918.
170. Schlenk, R.F., Dohner, K., Kneba, M., Gotze, K., Hartmann, F., Del Valle, F., Kirchen, H., Koller, E., Fischer, J.T., Bullinger, L., Habdank, M., Spath, D., Groner, S., Krebs, B., Kayser, S., Corbacioglu, A., Anhalt, A., Benner, A., Frohling, S., Dohner, H. & German-Austrian AML Study Group. (2009) Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. Haematologica, 94, 54-60.
171. Schlenk, R.F., Dohner, K., Mack, S., Stoppel, M., Kiraly, F., Gotze, K., Hartmann, F., Horst, H.A., Koller, E., Petzer, A., Grimminger, W., Kobbe, G., Glasmacher, A., Salwender, H., Kirchen, H., Haase, D., Kremers, S., Matzdorff, A., Benner, A. & Dohner, H. (2010) Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. Journal of Clinical Oncology, 28, 4642-4648.
172. Schlenk, R.F., Dohner, K., Krauter, J., Gaidzik, V.I., Paschka, P., Heuser, M., Kindler, T., Lubbert, M., Martin, H., Salih, H.R., Kuendgen, A., Horst, H.A., von Lilienfeld-Toal, M., Gotze, K., Nachbaur, D., Wattad, M., Kohne, C.-H., Fiedler, W., Bentz, M., Wulf, G., Held, G., Hertenstein, B., Mergenthaler, H.-G., Salwender, H., Rummel, M.J., Raghavachar, A., Benner, A., Schlegelberger, B., Ganser, A. & Dohner, H. (2011) All-trans retinoic acid improves outcome in younger adult patients with nucleophosmin-1 mutated acute myeloid leukemia - results of the AMLSG 07-04 randomized treatment trial. Blood (ASH Annual Meeting Abstracts), 118, Abstract 80.
173. Schliemann, C., Bieker, R., Padro, T., Kessler, T., Hintelmann, H., Buchner, T., Berdel, W.E. & Mesters, R.M. (2006) Expression of angiopoietins and their receptor Tie2 in the bone marrow of patients with acute myeloid leukemia. Haematologica, 91, 1203-1211.
174. Schneider, F., Hoster, E., Unterhalt, M., Schneider, S., Dufour, A., Benthaus, T., Mellert, G., Zellmeier, E., Kakadia, P.M., Bohlander, S.K., Feuring-Buske, M., Buske, C., Braess, J., Heinecke, A., Sauerland, M.C., Berdel, W.E., Buchner, T., Wormann, B.J., Hiddemann, W. & Spiekermann, K. (2012) The FLT3ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotype. Blood, 119, 4383-4386.
175. Schnittger, S., Weisser, M., Schoch, C., Hiddemann, W., Haferlach, T. & Kern, W. (2003) New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11 + acute myeloid leukemia based on quantification of fusion transcripts. Blood, 102, 2746-2755.
176. Schnittger, S., Kohl, T.M., Haferlach, T., Kern, W., Hiddemann, W., Spiekermann, K. & Schoch, C. (2006) KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood, 107, 1791-1799.
177. Schnittger, S., Kern, W., Tschulik, C., Weiss, T., Dicker, F., Falini, B., Haferlach, C. & Haferlach, T. (2009) Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood, 114, 2220-2231.
178. Schnittger, S., Haferlach, C., Ulke, M., Alpermann, T., Kern, W. & Haferlach, T. (2010) IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. Blood, 116, 5486-5496.
179. Schnittger, S., Bacher, U., Kern, W., Alpermann, T., Haferlach, C. & Haferlach, T. (2011a) Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia. Leukemia, 25, 1297-1304.
180. Schnittger, S., Dicker, F., Kern, W., Wendland, N., Sundermann, J., Alpermann, T., Haferlach, C. & Haferlach, T. (2011b) RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis. Blood, 117, 2348-2357.
181. Schnittger, S., Eder, C., Jeromin, S., Alpermann, T., Fasan, A., Grossmann, V., Kohlmann, A., Illig, T., Klopp, N., Wichmann, H.E., Kreuzer, K.A., Schmid, C., Staib, P., Peceny, R., Schmitz, N., Kern, W., Haferlach, C. & Haferlach, T. (2013) ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome. Leukemia, 27, 82-91.
182. Schoch, C., Kern, W., Schnittger, S., Buchner, T., Hiddemann, W. & Haferlach, T. (2004a) The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups. Haematologica, 89, 1082-1090.
183. Schoch, C., Kern, W., Schnittger, S., Hiddemann, W. & Haferlach, T. (2004b) Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia, 18, 120-125.
184. Schwind, S., Maharry, K., Radmacher, M.D., Mrozek, K., Holland, K.B., Margeson, D., Whitman, S.P., Hickey, C., Becker, H., Metzeler, K.H., Paschka, P., Baldus, C.D., Liu, S., Garzon, R., Powell, B.L., Kolitz, J.E., Carroll, A.J., Caligiuri, M.A., Larson, R.A., Marcucci, G. & Bloomfield, C.D. (2010) Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Journal of Clinical Oncology, 28, 5257-5264.
185. Serve, H., Krug, U., Wagner, R., Sauerland, M.C., Heinecke, A., Brunnberg, U., Schaich, M., Ottmann, O., Duyster, J., Wandt, H., Fischer, T., Giagounidis, A., Neubauer, A., Reichle, A., Aulitzky, W., Noppeney, R., Blau, I., Kunzmann, V., Stuhlmann, R., Krämer, A., Kreuzer, K.-A., Brandts, C., Steffen, B., Thiede, C., Müller-Tidow, C., Ehninger, G. & Berdel, W.E. (2013) Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. Journal of Clinical Oncology, 31, 3110-3118.
186. Shayegi, N., Kramer, M., Bornhäuser, M., Schaich, M., Schetelig, J., Platzbecker, U., Röllig, C., Heiderich, C., Landt, O., Ehninger, G. & Thiede, C. (2013) The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML. Blood, 122, 83-92.
187. Shen, Y., Zhu, Y.M., Fan, X., Shi, J.Y., Wang, Q.R., Yan, X.J., Gu, Z.H., Wang, Y.Y., Chen, B., Jiang, C.L., Yan, H., Chen, F.F., Chen, H.M., Chen, Z., Jin, J. & Chen, S.J. (2011) Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Blood, 118, 5593-5603.
188. Shimamoto, T., Ohyashiki, J.H. & Ohyashiki, K. (2005) Methylation of p15(INK4b) and E-cadherin genes is independently correlated with poor prognosis in acute myeloid leukemia. Leukemia Research, 29, 653-659.
189. Stelljes, M., Beelen, D.W., Braess, J., Sauerland, M.C., Heinecke, A., Berning, B., Kolb, H.J., Holler, E., Schwerdtfeger, R., Arnold, R., Spiekermann, K., Muller-Tidow, C., Serve, H.L., Silling, G., Hiddemann, W., Berdel, W.E., Buchner, T., Kienast, J. & for the German AML Coooperative Group (AMLCG). (2011) Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial. Haematologica, 96, 972-979.
190. Stelljes, M., Krug, U., Beelen, D.W., Braess, J., Sauerland, M.C., Heinecke, A., Ligges, S., Sauer, T., Tschanter, P., Thoennissen, G.B., Berning, B., Kolb, H.J., Reichle, A., Holler, E., Schwerdtfeger, R., Arnold, R., Scheid, C., Müller-Tidow, C., Woermann, B.J., Hiddemann, W., Berdel, W.E. & Büchner, T. (2013) Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis. Journal of Clinical Oncology, doi: 10.1200/JCO.2013.50.5768
191. Steudel, C., Wermke, M., Schaich, M., Schakel, U., Illmer, T., Ehninger, G. & Thiede, C. (2003) Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia. Genes Chromosomes Cancer, 37, 237-251.
192. Stirewalt, D.L., Kopecky, K.J., Meshinchi, S., Appelbaum, F.R., Slovak, M.L., Willman, C.L. & Radich, J.P. (2001) FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood, 97, 3589-3595.
193. Stirewalt, D.L., Kopecky, K.J., Meshinchi, S., Engel, J.H., Pogosova-Agadjanyan, E.L., Linsley, J., Slovak, M.L., Willman, C.L. & Radich, J.P. (2006) Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia. Blood, 107, 3724-3726.
194. Taby, R. & Issa, J.P. (2010) Cancer epigenetics. CA: a Cancer Journal for Clinicians, 60, 376-392.
195. Tang, J.L., Hou, H.A., Chen, C.Y., Liu, C.Y., Chou, W.C., Tseng, M.H., Huang, C.F., Lee, F.Y., Liu, M.C., Yao, M., Huang, S.Y., Ko, B.S., Hsu, S.C., Wu, S.J., Tsay, W., Chen, Y.C., Lin, L.I. & Tien, H.F. (2009a) AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood, 114, 5352-5361.
196. Tang, R., Hirsch, P., Fava, F., Lapusan, S., Marzac, C., Teyssandier, I., Pardo, J., Marie, J.P. & Legrand, O. (2009b) High Id1 expression is associated with poor prognosis in 237 patients with acute myeloid leukemia. Blood, 114, 2993-3000.
197. Terwijn, M., Feller, N., van Rhenen, A., Kelder, A., Westra, G., Zweegman, S., Ossenkoppele, G. & Schuurhuis, G.J. (2009) Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AML. European Journal of Cancer, 45, 1692-1699.
198. Terwijn, M., van Putten, W.L., Kelder, A., van der Velden, V.H., Brooimans, R.A., Pabst, T., Maertens, J., Boeckx, N., de Greef, G.E., Valk, P.J., Preijers, F.W., Huijgens, P.C., Dräger, A.M., Schanz, U., Jongen-Lavrecic, M., Biemond, B.J., Passweg, J.R., van Gelder, M., Wijermans, P., Graux, C., Bargetzi, M., Legdeur, M.C., Kuball, J., de Weerdt, O., Chalandon, Y., Hess, U., Verdonck, L.F., Gratama, J.W., Oussoren, Y.J., Scholten, W.J., Slomp, J., Snel, A.N., Vekemans, M.C., Löwenberg, B., Ossenkoppele, G.J. & Schuurhuis, G.J. (2013) High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. Journal of Clinical Oncology, 31, 3889-3897.
199. Thiede, C., Steudel, C., Mohr, B., Schaich, M., Schakel, U., Platzbecker, U., Wermke, M., Bornhauser, M., Ritter, M., Neubauer, A., Ehninger, G. & Illmer, T. (2002) Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood, 99, 4326-4335.
200. Thiede, C., Koch, S., Creutzig, E., Steudel, C., Illmer, T., Schaich, M. & Ehninger, G. (2006) Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood, 107, 4011-4020.
201. Thoennissen, N.H., Krug, U.O., Lee, D.H., Kawamata, N., Iwanski, G.B., Lasho, T., Weiss, T., Nowak, D., Koren-Michowitz, M., Kato, M., Sanada, M., Shih, L.Y., Nagler, A., Raynaud, S.D., Muller-Tidow, C., Mesa, R., Haferlach, T., Gilliland, D.G., Tefferi, A., Ogawa, S. & Koeffler, H.P. (2010) Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood, 115, 2882-2890.
202. Thol, F., Damm, F., Wagner, K., Gohring, G., Schlegelberger, B., Hoelzer, D., Lubbert, M., Heit, W., Kanz, L., Schlimok, G., Raghavachar, A., Fiedler, W., Kirchner, H., Heil, G., Heuser, M., Krauter, J. & Ganser, A. (2010) Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood, 116, 614-616.
203. Thol, F., Damm, F., Ludeking, A., Winschel, C., Wagner, K., Morgan, M., Yun, H., Gohring, G., Schlegelberger, B., Hoelzer, D., Lubbert, M., Kanz, L., Fiedler, W., Kirchner, H., Heil, G., Krauter, J., Ganser, A. & Heuser, M. (2011) Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. Journal of Clinical Oncology, 29, 2889-2896.
204. Tiesmeier, J., Muller-Tidow, C., Westermann, A., Czwalinna, A., Hoffmann, M., Krauter, J., Heil, G., Ganser, A., Serve, H. & Verbeek, W. (2004) Evolution of FLT3-ITD and D835 activating point mutations in relapsing acute myeloid leukemia and response to salvage therapy. Leukemia Research, 28, 1069-1074.
205. Treppendahl, M.B., Qiu, X., Sogaard, A., Yang, X., Nandrup-Bus, C., Hother, C., Andersen, M.K., Kjeldsen, L., Mollgaard, L., Hellstrom-Lindberg, E., Jendholm, J., Porse, B.T., Jones, P.A., Liang, G. & Gronbaek, K. (2012) Allelic methylation levels of the noncoding VTRNA2-1 located on chromosome 5q31.1 predict outcome in AML. Blood, 119, 206-216.
206. Tsimberidou, A.M., Kantarjian, H.M., Wen, S., O'Brien, S., Cortes, J., Wierda, W.G., Koller, C., Pierce, S., Brandt, M., Freireich, E.J., Keating, M.J. & Estey, E.H. (2008) The prognostic significance of serum beta2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1, 180 patients. Clinical Cancer Research, 14, 721-730.
207. Valk, P.J., Verhaak, R.G., Beijen, M.A., Erpelinck, C.A., Barjesteh van Waalwijk van Doorn-Khosrovani, S., Boer, J.M., Beverloo, H.B., Moorhouse, M.J., van der Spek, P.J., Lowenberg, B. & Delwel, R. (2004) Prognostically useful gene-expression profiles in acute myeloid leukemia. New England Journal of Medicine, 350, 1617-1628.
208. van der Velden, V.H., van der Sluijs-Geling, A., Gibson, B.E., te Marvelde, J.G., Hoogeveen, P.G., Hop, W.C., Wheatley, K., Bierings, M.B., Schuurhuis, G.J., de Graaf, S.S., van Wering, E.R. & van Dongen, J.J. (2010) Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol. Leukemia, 24, 1599-1606.
209. Verhaak, R.G., Goudswaard, C.S., van Putten, W., Bijl, M.A., Sanders, M.A., Hugens, W., Uitterlinden, A.G., Erpelinck, C.A., Delwel, R., Lowenberg, B. & Valk, P.J. (2005) Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood, 106, 3747-3754.
210. Virappane, P., Gale, R., Hills, R., Kakkas, I., Summers, K., Stevens, J., Allen, C., Green, C., Quentmeier, H., Drexler, H., Burnett, A., Linch, D., Bonnet, D., Lister, T.A. & Fitzgibbon, J. (2008) Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. Journal of Clinical Oncology, 26, 5429-5435.
211. Wagner, K., Damm, F., Gohring, G., Gorlich, K., Heuser, M., Schafer, I., Ottmann, O., Lubbert, M., Heit, W., Kanz, L., Schlimok, G., Raghavachar, A.A., Fiedler, W., Kirchner, H.H., Brugger, W., Zucknick, M., Schlegelberger, B., Heil, G., Ganser, A. & Krauter, J. (2010) Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. Journal of Clinical Oncology, 28, 2356-2364.
212. Walter, R.B., Gooley, T.A., Wood, B.L., Milano, F., Fang, M., Sorror, M.L., Estey, E.H., Salter, A.I., Lansverk, E., Chien, J.W., Gopal, A.K., Appelbaum, F.R. & Pagel, J.M. (2011) Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. Journal of Clinical Oncology, 29, 1190-1197.
213. Weisser, M., Haferlach, C., Hiddemann, W. & Schnittger, S. (2007) The quality of molecular response to chemotherapy is predictive for the outcome of AML1-ETO-positive AML and is independent of pretreatment risk factors. Leukemia, 21, 1177-1182.
214. Whitman, S.P., Archer, K.J., Feng, L., Baldus, C., Becknell, B., Carlson, B.D., Carroll, A.J., Mrozek, K., Vardiman, J.W., George, S.L., Kolitz, J.E., Larson, R.A., Bloomfield, C.D. & Caligiuri, M.A. (2001) Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Research, 61, 7233-7239.
215. Whitman, S.P., Ruppert, A.S., Radmacher, M.D., Mrozek, K., Paschka, P., Langer, C., Baldus, C.D., Wen, J., Racke, F., Powell, B.L., Kolitz, J.E., Larson, R.A., Caligiuri, M.A., Marcucci, G. & Bloomfield, C.D. (2008) FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood, 111, 1552-1559.
216. Whitman, S.P., Maharry, K., Radmacher, M.D., Becker, H., Mrozek, K., Margeson, D., Holland, K.B., Wu, Y.Z., Schwind, S., Metzeler, K.H., Wen, J., Baer, M.R., Powell, B.L., Carter, T.H., Kolitz, J.E., Wetzler, M., Moore, J.O., Stone, R.M., Carroll, A.J., Larson, R.A., Caligiuri, M.A., Marcucci, G. & Bloomfield, C.D. (2010) FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood, 116, 3622-3626.
217. Will, B. & Steidl, U. (2010) Multi-parameter fluorescence-activated cell sorting and analysis of stem and progenitor cells in myeloid malignancies. Best Practice & Research. Clinical Haematology, 23, 391-401.
218. Wouters, B.J., Lowenberg, B., Erpelinck-Verschueren, C.A., van Putten, W.L., Valk, P.J. & Delwel, R. (2009) Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood, 113, 3088-3091.
219. Yan, X.J., Xu, J., Gu, Z.H., Pan, C.M., Lu, G., Shen, Y., Shi, J.Y., Zhu, Y.M., Tang, L., Zhang, X.W., Liang, W.X., Mi, J.Q., Song, H.D., Li, K.Q., Chen, Z. & Chen, S.J. (2011) Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nature Genetics, 43, 309-315.
220. Yanada, M., Kurosawa, S., Yamaguchi, T., Yamashita, T., Moriuchi, Y., Ago, H., Takeuchi, J., Nakamae, H., Taguchi, J., Sakura, T., Takamatsu, Y., Waki, F., Yokoyama, H., Watanabe, M., Emi, N. & Fukuda, T. (2012) Prognosis of acute myeloid leukemia harboring monosomal karyotype in patients treated with or without allogeneic hematopoietic cell transplantation after achieving complete remission. Haematologica, 97, 915-918.
221. Yang, D.H., Lee, J.J., Mun, Y.C., Shin, H.J., Kim, Y.K., Cho, S.H., Chung, I.J., Seong, C.M. & Kim, H.J. (2007) Predictable prognostic factor of CD56 expression in patients with acute myeloid leukemia with t(8:21) after high dose cytarabine or allogeneic hematopoietic stem cell transplantation. American Journal of Hematology, 82, 1-5.
222. Yin, J.A., O'Brien, M.A., Hills, R.K., Daly, S.B., Wheatley, K. & Burnett, A.K. (2012) Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood, 120, 2826-2835.
223. Young, H.E., Steele, T.A., Bray, R.A., Detmer, K., Blake, L.W., Lucas, P.W. & Black, A.C. Jr (1999) Human pluripotent and progenitor cells display cell surface cluster differentiation markers CD10, CD13, CD56, and MHC class-I. Proceedings of the Society for Experimental Biology & Medicine, 221, 63-71.
224. Zhang, Y., Wei, H., Wang, M., Huai, L., Mi, Y., Lin, D., Liu, B., Li, W., Zhou, C., Rao, Q. & Wang, J. (2011) Some novel features of IDH1-mutated acute myeloid leukemia revealed in Chinese patients. Leukemia Research, 35, 1301-1306.
225. Zhou, K.G., Jiang, L.J., Shang, Z., Wang, J., Huang, L. & Zhou, J.F. (2012) Potential application of IDH1 and IDH2 mutations as prognostic indicators in non-promyelocytic acute myeloid leukemia: a meta-analysis. Leukemia & Lymphoma, 53, 2423-2429.